Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

A federal judge in West Virginia denied Regeneron's request for an injunction against Amgen's Pavblu, creating uncertainty around Eylea's U.S. market exclusivity. At the time, Leerink's Risinger ...

Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET. Company Participants. Ryan Crowe - SVP, IR & Strat ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...

Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Market Perform to Outperform. As of January 28, 2025 ...

Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (LSE:0R2M) from Market Perform to Outperform. There are 2,471 funds or institutions ...

Abecma made $406 million in 2024, of which BMS paid $43 million to 2seventy bio as part of their profit-sharing agreement.

In addition to Truist Financial, Regeneron also received a Buy from Oppenheimer’s Matthew Biegler in a report issued today. However, on January 28, Leerink Partners maintained a Hold rating on ...

The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.

In a report released on March 2, David Risinger from Leerink Partners maintained a Hold rating on Amgen (AMGN – Research Report). The company’s ...

Leerink Partners upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a market perform rating to an outperform rating in a research report released on Wednesday ...